In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
After finishing at $0.32 in the prior trading day, BioXcel Therapeutics Inc (NASDAQ: BTAI) closed at $0.34, up 8.12%. In other words, the price has increased by $8.12 from its previous closing price. On the day, 0.83 million shares were traded. BTAI stock price reached its highest trading level at $0.3441 during the session, while it also had its lowest trading level at $0.3001.
Ratios:
Our goal is to gain a better understanding of BTAI by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.81 and its Current Ratio is at 1.87.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, UBS on February 21, 2024, Downgraded its rating to Neutral and sets its target price to $4 from $9 previously.
On August 15, 2023, Mizuho Downgraded its rating to Neutral which previously was Buy and also lowered its target price recommendation from $40 to $4.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 16 ’24 when O’Neill Vincent sold 165 shares for $0.35 per share. The transaction valued at 58 led to the insider holds 19,957 shares of the business.
Mehta Vimal sold 3,117 shares of BTAI for $1,131 on Dec 16 ’24. The CEO and President now owns 59,605 shares after completing the transaction at $0.36 per share. On Dec 16 ’24, another insider, Steinhart Richard I, who serves as the Chief Financial Officer of the company, sold 577 shares for $0.36 each. As a result, the insider received 207 and left with 20,932 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BTAI now has a Market Capitalization of 16486804 and an Enterprise Value of 68555056. For the stock, the TTM Price-to-Sale (P/S) ratio is 8.02. Its current Enterprise Value per Revenue stands at 28.529 whereas that against EBITDA is -0.657.
Stock Price History:
Over the past 52 weeks, BTAI has reached a high of $4.17, while it has fallen to a 52-week low of $0.32. The 50-Day Moving Average of the stock is -36.42%, while the 200-Day Moving Average is calculated to be -73.69%.
Shares Statistics:
The stock has traded on average 611.45K shares per day over the past 3-months and 1082740 shares per day over the last 10 days, according to various share statistics. A total of 42.46M shares are outstanding, with a floating share count of 41.10M. Insiders hold about 17.18% of the company’s shares, while institutions hold 11.89% stake in the company. Shares short for BTAI as of 1730332800 were 347081 with a Short Ratio of 1.47, compared to 1727654400 on 516384. Therefore, it implies a Short% of Shares Outstanding of 347081 and a Short% of Float of 1.09.
